GSK fights back against Senate's "flawed" Avandia report
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has leapt to the defence of its once-blockbuster diabetes drug Avandia (rosiglitazone) after it came under fire earlier this week from a US Senate inquiry into the drug's safety (scripnews.com, February 22nd, 2010). The UK company has responded with a 30-page retort to the allegations of misconduct, claiming the Senate's report is not "accurate, balanced, or complete".